Company intelligence / Profile preview

Infinity Technology

Baltimore, Maryland, USAinfinitybio.com ↗

Ownership: Private
Development stage: Other

Overview

Infinity Bio has developed proprietary technology to map the human antibody reactome at high resolution. Their MIPSA™ platform enables unbiased analysis of immune responses for applications including biomarker discovery and translational research. The company recently closed an $8M Series A round led by Illumina Ventures to expand its offerings after acquiring assets from Serimmune. New products such as EnviroSIGHT™ are expected to launch in late 2025. No direct clinical results since they do not develop therapeutics themselves.

Industry: Drug Discovery Services

Partnerships

Illumina VenturesPTX CapitalBlackbird BioVenturesPropel Baltimore Fund

Beyond the preview

Go deeper on Infinity Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infinity Technology.

Explore the full profile